$2.01
3.61% today
Nasdaq, Apr 02, 10:13 pm CET
ISIN
US6294441000
Symbol
NRXP
Sector
Industry

NRX Pharmaceuticals Inc Stock price

$1.94
-0.09 4.43% 1M
+0.33 20.50% 6M
-0.26 11.82% YTD
-3.31 63.05% 1Y
-22.26 91.98% 3Y
-104.06 98.17% 5Y
-94.06 97.98% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.11 5.37%
ISIN
US6294441000
Symbol
NRXP
Sector
Industry

Key metrics

Market capitalization $32.82m
Enterprise Value $37.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-19.70m
Free Cash Flow (TTM) Free Cash Flow $-10.64m
Cash position $1.44m
EPS (TTM) EPS $-2.41
P/E forward negative
P/S forward 0.45
EV/Sales forward 0.52
Short interest 6.81%
Show more

Is NRX Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

NRX Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a NRX Pharmaceuticals Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a NRX Pharmaceuticals Inc forecast:

Buy
100%

Financial data from NRX Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
0% 0%
-
-0.01 -0.01
0% 0%
-
- Selling and Administrative Expenses 14 14
5% 5%
-
- Research and Development Expense 6.20 6.20
54% 54%
-
-20 -20
29% 29%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -20 -20
29% 29%
-
Net Profit -25 -25
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about NRX Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NRX Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
2 days ago
Dura Medical, together with previously-announced acquisition of Neurospa TMS, will provide coverage throughout the West Coast of Florida Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients Stephen Durand, founder of Dura, to serve as Director of Clinic Oper...
Neutral
PRNewsWire
9 days ago
Neurospa currently operates six interventional psychiatry clinics on Florida's Gulf Coast HOPE to acquire majority interest in Neurospa for a combination of cash and equity Neurospa clinics deliver a full range of interventional psychiatry services, including Ketamine, Spravato ® and Transcranial Magnetic Stimulation (TMS) to patients with severe depression and related conditions Acquisition to...
Neutral
Seeking Alpha
16 days ago
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Michael Abrams - Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital Thomas Shrader - BTIG Vernon Bernardino - H.C.
More NRX Pharmaceuticals Inc News

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Head office United States
CEO Jonathan Javitt
Founded 2017
Website www.nrxpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today